Funder
Javna Agencija za Raziskovalno Dejavnost RS
Publisher
Springer Science and Business Media LLC
Subject
Applied Microbiology and Biotechnology,General Medicine,Biotechnology
Reference140 articles.
1. ActoBio Therapeutics I (2018) ActoBio Therapeutics™ doses first patient in phase Ib/IIa clinical study of AG019 for the treatment of type 1 diabetes. PW Newswire.
https://www.prnewswire.com/news-releases/actobio-therapeutics-doses-first-patient-in-phase-ibiia-clinical-study-of-ag019-for-the-treatment-of-type-1-diabetes-300739137.html
. Accessed 29 Oct 2018
2. Arora T, Wegmann U, Bobhate A, Lee YS, Greiner TU, Drucker DJ, Narbad A, Backhed F (2016) Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice. Mol Metab 5(8):725–730
3. de Azevedo M, Karczewski J, Lefevre F, Azevedo V, Miyoshi A, Wells JM, Langella P, Chatel JM (2012) In vitro and in vivo characterization of DNA delivery using recombinant Lactococcus lactis expressing a mutated form of L. monocytogenes Internalin a. BMC Microbiol 12:299
4. Bahey-El-Din M, Gahan CG (2011) Lactococcus lactis-based vaccines: current status and future perspectives. Hum Vaccin 7(1):106–109
5. Bahey-El-Din M, Casey PG, Griffin BT, Gahan CG (2010) Efficacy of a Lactococcus lactis DeltapyrG vaccine delivery platform expressing chromosomally integrated hly from Listeria monocytogenes. Bioeng Bugs 1(1):66–74.
https://doi.org/10.4161/bbug.1.1.10284
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献